Cipla Bets On Advair Generic To Power U.S. Sales
This article was originally published in PharmAsia News
Executive Summary
Cipla’s development plans place a big bet on the U.S. launch of a generic version of GlaxoSmithKline's Advair (fluticasone) for treating asthma.